A Phase 1/2 interventional study of Nanodrop® and Systane Balance in Dry Eye, sponsored by Laboratorios Sophia S.A de C.V.. Completed at 6 sites in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-16.
Sponsored by Laboratorios Sophia S.A de C.V. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing Propylene Glycol in Dry Eye Syndromes — 3 open to participants now, 3 under way, none of them phase 3. Propylene Glycol · Dry Eye Syndromes.
Among the 12 studies testing Propylene Glycol in Dry Eye Syndromes, this one is the 4th largest by enrollment, is the only one that started in 2020, is the only one in phase 1/2, and was the 8th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →3 of the 12 studies testing Propylene Glycol in Dry Eye Syndromes are open now, in 2 countries. Recruiting first, the newest first:
Andover Research Eye Institute · Sites in United States
Ages 18+
National Taiwan University Hospital · Sites in Taiwan
Ages 20–85
National Taiwan University Hospital · Sites in Taiwan
Ages 20–85
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2020.
This study's enrollment of 126 is above the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 87 across the 12 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 12 have an industry lead sponsor. The 9 most frequent:
Laboratorios Sophia S.A de C.V. is the lead sponsor of 45 studies on the registry; 5 are open to participants now.
13 studies in Dry Eye Syndromes by Laboratorios Sophia S.A de C.V.: 2 open now, 2 under way, none of them phase 3. Of 11 finished, 10 (91%) have results posted.
Among the 13 studies in Dry Eye Syndromes by Laboratorios Sophia S.A de C.V., this one is the 5th largest by enrollment, is the only one that started in 2020, is the only one in phase 1/2, and was the 8th registered.
Laboratorios Sophia S.A de C.V.’s Dry Eye Syndromes studies by the year they started, since 2011.
1 of the studies testing Propylene Glycol in Dry Eye Syndromes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06763731National Taiwan University HospitalOptimizing the Ocular Surface With Systane COMPLETE in Patients With Dry Eye Planning for Cataract Surgery | 2027-01-14 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing Propylene Glycol in Dry Eye Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Laboratorios Sophia S.A de C.V.’s 13 in Dry Eye Syndromes:
This tab as a report to print or save as PDF → With an account.
Study design:
Phase I-II clinical trial, comparative, non-inferiority with active control, parallel groups, double blind with randomisation. Safety analysis when completing the visits of the first 12 subjects of the Nanodrop® group, if there are less than 20% of unexpected Events (EA), related to the research product, recruitment is continued until the sample is completed for efficacy analysis
objectives Security: Evaluate the safety of the ophthalmic application of Nanodrop® by quantifying the incidence of unexpected Adverse Events (EA) related to the research product (PI).
Effectiveness: Demonstrate the non-inferiority of Nanodrop® compared to Systane® Balance, in the efficacy of the treatment of patients with dry eye, by means of the Ocular Surface Disease Index (OSDI).
Hypothesis
Security:
H0 = Nanodrop® is safe in its ophthalmic application as it presents an incidence of unexpected adverse events related to the research drug, less than 20% of the population of Nanodrop® safety group.
H1 = Nanodrop® is not safe in its ophthalmic application, as it presents an incidence of unexpected adverse events related to the research drug, exceeding 20% of the population of Nanodrop® safety group.
Effectiveness:
H0 = Nanodrop® is lower than Systane® Balance by more than 5 points in the OSDI test score.
H1 = Nanodrop® is lower than Systane® Balance by 5 points or less in the OSDI test score.
Number of subjects: n = 126 evaluable subjects 63 evaluable subjects per group (both eyes).
Main inclusion criteria: Dry eye diagnosis
Duration of intervention treatment: 28 days Approximate duration of the subject in the study: 35 days
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
OSDI ≥ 13 points plus one of the following:
Exclusion Criteria:
Allergic, viral or bacterial conjunctivitis. Anterior blepharitis. Demodex. Eye parasitic infections. Unresolved eye trauma. Healing diseases of the ocular surface. Corneal or conjunctival ulcers. Filamentous keratitis. Neurotrophic keratitis. Bullous keratopathy. Neoplastic diseases on the ocular surface or annexes. Diseases with fibrovascular proliferations on the conjunctival and / or corneal surface.
Diseases in the retina and / or posterior segment that require treatment or threaten the visual prognosis.
Glaucoma
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
\- Nanodrop®. 0.6% propylene glycol. Ophthalmic emulsion Laboratorios Sophia, S.A. from C.V. Route of administration: Ophthalmic.
Drug: Nanodrop®
* Systane® Balance. 0.6% propylene glycol. Ophthalmic emulsion Alcon Laboratories, Inc. * Route of administration: Ophthalmic.
Drug: Systane Balance
minimum to meet 1 drop 4 times a day, both eyes
Also known as: PRO-176, Propylene glycol 0.6%
minimum to meet 1 drop 4 times a day, both eyes
Also known as: Propylene glycol 0.6%
Ocular Surface Disease Index (OSDI)
OSDI is a questionnaire designed to measure eye surface irritation with Rasch analysis to produce estimates on a linear interval scale.. The OSDI score ranges from 0 to 100, with higher scores indicating greater severity of symptoms. A score of 0 represents no symptoms, while 100 represents the most severe symptoms.
Time frame: will be evaluated at the end of the treatment (day 29, final visit)
Percentage of Unexpected Adverse Events (AE) Related to the Research Product
the adverse events will be evaluated with a scale of Present / Absent, it is a nominal variable, the normal value is absent
Time frame: during the 29 days of evaluation, including the safety call
Visual Acuity (VA)
Visual acuity (VA) is a test of visual function. It will be evaluated with the Snellen chart. The Snellen chart is the standard tool used to evaluate visual acuity. It was located in a place with adequate lighting, natural or artificial and at a distance of 3 meters from the subject to be evaluated. The contralateral eye to which it will be evaluated is covered, then the examiner detects until the line can clearly see the letters given he or she a score, the normal score for a VA is 20/20.This score can be expressed in fraction (i.e. 20/20) decimal (i.e. 1.0), or LogMAR (i.e. 0) formats. In this study, VA is expressed in decimal format. In decimal format, a lower number is a worse outcome.
Time frame: will be evaluated at the end of the treatment (day 29, final visit)
Epithelial Defects (ED) Fluorescein Stain
The epithelial defects will be evaluated by fluorescein, it is a discrete variable that will be realized by direct observation, It will be qualified according to the Eye Staining Rating (CTO) of the International Alliance of Clinical Collaboration of Sjögren (SICCA).According to the CTO, grade 0 corresponds to the absence of dotted epithelial erosions (EEP); Grade 1 is defined as the presence of 1-5 EEP; Grade 2 corresponds to 6-30 EEP; and\> 30 EEP will be classified as grade 3. Additionally a qualification point will be added if: 1) EEP is presented in the central portion of the cornea with a diameter of 4mm; 2) filaments are observed and 3) confluent staining patches are observed, including linear stains. A greater score is a worse outcome.
Time frame: will be evaluated at the end of the treatment (day 29, final visit)
Epithelial Defects (ED) Green Lissamine
The epithelial defects will be evaluated by green lissamine, it is a discrete variable that will be realized by direct observation, It will be qualified according to the Eye Staining Rating (CTO) of the International Alliance of Clinical Collaboration of Sjögren (SICCA). In the CTO, grade 0 is defined as the presence of 0 to 9 lissamine green staining points in the interpalpebral bulbar conjunctiva (qualifying the temporal and nasal portion separately); grade 1 is defined by the presence of 10 to 32 points; grade 2 by 33 to 100; and grade 3 for\> 100 points. Due to the difficulty of counting individual points in a moving eye, any area ≥ 4mm2 of confluent points is considered\> 100 points. A higher score is a worse outcome.
Time frame: will be evaluated at the end of the treatment (day 29, final visit)
Incidence of Expected Adverse Events
the adverse events will be evaluated with a scale of Present / Absent, it is a nominal variable, the normal value is absent
Time frame: will be evaluated at the end of the treatment (day 29, final visit)
Tear Breakup Time (TBUT)
brake up time of the tear film One of the first aspects of the tear film that changes when there is an alteration to the ocular surface is its stability. In general, if the corneal or conjunctival surface is damaged, it is unlikely that a stable tear film can be maintained. The most common method to evaluate tear film stability is the evaluation of TBUT with fluorescein. Once the fluorescein is instilled, with the cobalt blue filter the patient is asked not to blink after having blinked 1 to 2 times. The colored precorneal fluorescein layer will change to less fluorescent or non-fluorescent regions. The time that elapses from the last blink to the appearance of these regions is the TBUT. It will be reported in seconds.
Time frame: will be evaluated at the end of the treatment (day 29, final visit)
| Milestone | Nanodrop® (PRO-176) | Systane® Balance |
|---|---|---|
| Started | 63 | 63 |
| Completed | 56 | 59 |
| Not completed | 7 | 4 |
OSDI is a questionnaire designed to measure eye surface irritation with Rasch analysis to produce estimates on a linear interval scale.. The OSDI score ranges from 0 to 100, with higher scores indicating greater severity of symptoms. A score of 0 represents no symptoms, while 100 represents the most severe symptoms.
| score on a scale | Nanodrop® (PRO-176) | Systane® Balance |
|---|---|---|
| Ocular Surface Disease Index (OSDI) | 48.9 ± 19.2 | 50.3 ± 18.3 |
the adverse events will be evaluated with a scale of Present / Absent, it is a nominal variable, the normal value is absent
| percentage of unexpected related AE | Nanodrop® (PRO-176) | Systane® Balance |
|---|---|---|
| Percentage of Unexpected Adverse Events (AE) Related to the Research Product | 23.0 | 17.5 |
Visual acuity (VA) is a test of visual function. It will be evaluated with the Snellen chart. The Snellen chart is the standard tool used to evaluate visual acuity. It was located in a place with adequate lighting, natural or artificial and at a distance of 3 meters from the subject to be evaluated. The contralateral eye to which it will be evaluated is covered, then the examiner detects until the line can clearly see the letters given he or she a score, the normal score for a VA is 20/20.This score can be expressed in fraction (i.e. 20/20) decimal (i.e. 1.0), or LogMAR (i.e. 0) formats. In this study, VA is expressed in decimal format. In decimal format, a lower number is a worse outcome.
| decimal score (Snellen Chart) | Nanodrop® (PRO-176) | Systane® Balance |
|---|---|---|
| Visual Acuity (VA) | 0.89 ± 0.18 | 0.90 ± 0.19 |
The epithelial defects will be evaluated by fluorescein, it is a discrete variable that will be realized by direct observation, It will be qualified according to the Eye Staining Rating (CTO) of the International Alliance of Clinical Collaboration of Sjögren (SICCA).According to the CTO, grade 0 corresponds to the absence of dotted epithelial erosions (EEP); Grade 1 is defined as the presence of 1-5 EEP; Grade 2 corresponds to 6-30 EEP; and\> 30 EEP will be classified as grade 3. Additionally a qualification point will be added if: 1) EEP is presented in the central portion of the cornea with a diameter of 4mm; 2) filaments are observed and 3) confluent staining patches are observed, including linear stains. A greater score is a worse outcome.
| score on a scale | Nanodrop® (PRO-176) | Systane® Balance |
|---|---|---|
| Epithelial Defects (ED) Fluorescein Stain | 0.91 ± 0.92 | 0.93 ± 1.14 |
The epithelial defects will be evaluated by green lissamine, it is a discrete variable that will be realized by direct observation, It will be qualified according to the Eye Staining Rating (CTO) of the International Alliance of Clinical Collaboration of Sjögren (SICCA). In the CTO, grade 0 is defined as the presence of 0 to 9 lissamine green staining points in the interpalpebral bulbar conjunctiva (qualifying the temporal and nasal portion separately); grade 1 is defined by the presence of 10 to 32 points; grade 2 by 33 to 100; and grade 3 for\> 100 points. Due to the difficulty of counting individual points in a moving eye, any area ≥ 4mm2 of confluent points is considered\> 100 points. A higher score is a worse outcome.
| score on a scale | Nanodrop® (PRO-176) | Systane® Balance |
|---|---|---|
| Epithelial Defects (ED) Green Lissamine | 0.83 ± 0.69 | 0.85 ± 0.78 |
the adverse events will be evaluated with a scale of Present / Absent, it is a nominal variable, the normal value is absent
| percentage of adverse events per group | Nanodrop® (PRO-176) | Systane® Balance |
|---|---|---|
| Incidence of Expected Adverse Events | 77 | 82.5 |
brake up time of the tear film One of the first aspects of the tear film that changes when there is an alteration to the ocular surface is its stability. In general, if the corneal or conjunctival surface is damaged, it is unlikely that a stable tear film can be maintained. The most common method to evaluate tear film stability is the evaluation of TBUT with fluorescein. Once the fluorescein is instilled, with the cobalt blue filter the patient is asked not to blink after having blinked 1 to 2 times. The colored precorneal fluorescein layer will change to less fluorescent or non-fluorescent regions. The time that elapses from the last blink to the appearance of these regions is the TBUT. It will be reported in seconds.
| reported in seconds | Nanodrop® (PRO-176) | Systane® Balance |
|---|---|---|
| Tear Breakup Time (TBUT) | 2.28 ± 2.9 | 2.02 ± 2.9 |
Collected over Time frame will be evaluated from day 1 (basal visit) to the final visit day 28 (±1 days).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nanodrop® (PRO-176) | 0/63 (0%) | 0/63 (0%) | 54/63 (85.7%) |
| Systane® Balance | 0/63 (0%) | 1/63 (1.6%) | 47/63 (74.6%) |
| Event | Nanodrop® (PRO-176) | Systane® Balance |
|---|---|---|
| COVID-19Respiratory, thoracic and mediastinal disorders | 0/63 | 1/63 |
| Event | Nanodrop® (PRO-176) | Systane® Balance |
|---|---|---|
| Burning sensationEye disorders | 37/63 | 23/63 |
| ineffective drugProduct Issues | 13/63 | 16/63 |
| pruritusEye disorders | 11/63 | 13/63 |
| blurred visionEye disorders | 4/63 | 11/63 |
| conjunctival hyperemiaEye disorders | 8/63 | 8/63 |
| headacheNervous system disorders | 7/63 | 1/63 |
| Irritation in the area of instillationEye disorders | 5/63 | 3/63 |
| tearingEye disorders | 1/63 | 5/63 |
| sensation of ocular painEye disorders | 3/63 | 4/63 |
| conjunctivitisEye disorders | 4/63 | 2/63 |
The manifested adverse events during the conduction of this trial were obtained during trial visits and reported in the electronic CRF, where the clinical team of the center included the information from source documents. These were previously checked by the monitor team, pharmacovigilance specialist, and the medical specialist part of the sponsor's crew to verify concordance with what was stipulated in the protocol.
| Age, Categorical(Participants) | Nanodrop® (PRO-176) | Systane® Balance | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 53 | 57 | 110 |
| >=65 years | 10 | 6 | 16 |
| Age, Continuous(years) | Nanodrop® (PRO-176) | Systane® Balance | Total |
|---|---|---|---|
| Mean | 47.8 ± 17.4 | 44.6 ± 15.4 | 46.18 ± 16.45 |
| Sex: Female, Male(Participants) | Nanodrop® (PRO-176) | Systane® Balance | Total |
|---|---|---|---|
| Female | 47 | 40 | 87 |
| Male | 16 | 23 | 39 |
| Race and Ethnicity Not Collected(Participants) | Nanodrop® (PRO-176) | Systane® Balance | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Nanodrop® (PRO-176) | Systane® Balance | Total |
|---|---|---|---|
| Mexico | 63 | 63 | 126 |
| Intraocular Pressure (IOP)(mmhg) | Nanodrop® (PRO-176) | Systane® Balance | Total |
|---|---|---|---|
| Mean | 13.8 ± 3.1 | 12.7 ± 2.5 | 13.20 ± 3.41 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2020 to primary completion in Dec 2021, 12 months.
Results were first posted in Jul 2025, 3 years 7 months after primary completion.
Of 21 phase 1/2 interventional studies under Dry Eye Syndromes, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Propylene Glycol
Laboratorios Sophia S.A de C.V. →